ACIU Stock Rallies 16.3% in a Week: Here's What You Need to Know

AC Immune expanded its agreement with Eli Lilly to add next‑generation Tau Morphomer candidates, bolstering its long‑term Alzheimer’s pipeline and strategic partnership. The move drove a stock gain and should modestly improve AC Immune’s R&D optionality and valuation prospects through strengthened collaboration with a top‑tier pharma partner.

Analysis

AC Immune expanded its agreement with Eli Lilly to add next‑generation Tau Morphomer candidates, bolstering its long‑term Alzheimer’s pipeline and strategic partnership. The move drove a stock gain and should modestly improve AC Immune’s R&D optionality and valuation prospects through strengthened collaboration with a top‑tier pharma partner.